BCAXBicara TherapeuticsSigning up patients
A Study Evaluating Ficerafusp Alfa (BCA101) QW in Combination With Pembrolizumab vs Alternative Ficerafusp Alfa Dosing in 1L R or M HNSCC
Metastatic Head and Neck Squamous Cell Carcinoma · Recurrent Head and Neck Squamous Cell Carcinoma
0Calmworry score, out of 100
No strong warning signs right now. The score counts warning signs; it is not a prediction.
Why this score
No warning signs right now. That's why the score is 0.
Score over time
- Stage
- Phase 2
- Patients
- 160 (planned)
- Started
- Sep 2026
- Main results expected
- Mar 2028
- Fully finished
- Mar 2029
- Results posted
- not yet
What counts as success
The trial's main goal(s), called the “primary outcome.”
Proportion of participants in maintenance phase who are progression-free as assessed by blinded independent central review (BICR) per RECIST 1.1 and alive.
Measured over: Approximately 9 months.
Changes Tremor has spotted
No changes since Tremor started watching this trial.
Show details (technical version)
Score inputs
- none
Raw record changes
- none yet
Trial ID NCT07807163 · record last updated 2026-10-13 · checked 2026-11-09 15:42 UTC